Core Viewpoint - The news summarizes important announcements from various companies, highlighting stock suspensions, significant profit growth, and major contracts signed, which may present investment opportunities and insights into market trends [1][2]. Stock Suspensions - *ST Zhengping announced that its stock will be suspended from trading starting October 29, 2025, due to a significant price increase of 152.42% from September 1 to October 28, 2025, and abnormal trading fluctuations [3]. - Gongjin Co. announced a stock suspension starting October 27, 2025, due to the major shareholder planning a share transfer that may lead to a change in control [4]. Investment Activities - Juyuan Technology's subsidiary plans to invest 150 million yuan in establishing an industrial fund focused on chips, integrated circuits, and other high-growth sectors [5]. - YN Holdings decided to terminate investments in 17 distributed photovoltaic projects, originally planned to cost 1.197 billion yuan, due to changes in market conditions [6]. Earnings Reports - Suliy Co. reported a 2750% increase in net profit for Q3 2025, with revenue of 762 million yuan, up 26% year-on-year [8]. - Xianda Co. reported a net profit of 59.85 million yuan for Q3 2025, a 5447% increase, despite a 5.59% decline in revenue [9]. - Yutong Bus reported a net profit of 1.357 billion yuan for Q3 2025, a 78.98% increase, with revenue of 10.237 billion yuan, up 32.27% [10]. - Juxin Technology reported a net profit of 60.27 million yuan for Q3 2025, a 101.09% increase, with revenue of 273 million yuan, up 46.64% [11]. - Guanghong Technology reported a net profit of 99.61 million yuan for Q3 2025, a 99.68% increase, with revenue of 2.937 billion yuan, up 57.46% [12]. - Mingzhi Electric reported a net profit of 22.88 million yuan for Q3 2025, a 215.97% increase, with revenue of 729 million yuan, up 28.98% [13]. - Zhongwei Semiconductor reported a net profit of 65.82 million yuan for Q3 2025, a 3.66% decrease, with revenue of 269 million yuan, up 21.88% [14]. - Yiming Pharmaceutical reported a net profit of 44.21 million yuan for Q3 2025, a 1934.12% increase, with revenue of 178 million yuan, up 10.37% [15]. - Weilan Bio reported a net profit of 35.06 million yuan for Q3 2025, a 205.02% increase, with revenue of 364 million yuan, up 8.09% [16]. - Baiyunshan reported a net profit of 794 million yuan for Q3 2025, a 30.28% increase, with revenue of 19.771 billion yuan, up 9.74% [17]. - Giant Network reported a net profit of 640 million yuan for Q3 2025, an 81.19% increase, with revenue of 1.706 billion yuan, up 115.63% [18]. Share Buybacks - Haida Group announced a plan to repurchase shares worth between 1 billion and 1.6 billion yuan, aimed at reducing registered capital and implementing employee stock ownership plans [20]. Major Contracts - Bai'ao Intelligent announced it won a project worth 97.22 million yuan from a large state-owned company [22]. - Guangdong Construction signed a construction contract worth 1.924 billion yuan for a project in Guangzhou, with a duration of 1365 days [23][24].

Core Insights - The company reported a revenue of 1.016 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.42% [1] - The net profit attributable to shareholders reached 61.78 million yuan, showing a significant year-on-year increase of 51.24% [1] - The non-recurring net profit was 22.93 million yuan, which reflects a slight decline of 1.47% year-on-year [1] - The basic earnings per share stood at 0.24 yuan [1]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-049 青岛蔚蓝生物股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 5 日（星期三）上午 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 29 日（星期三）至 11 月 4 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 vland@vlandgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 青岛蔚蓝生物股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度的经营成果、财务状 ...

青岛蔚蓝生物股份有限公司 关于增值税税率调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、增值税税率调整的基本情况 根据《财政部 国家税务总局关于部分货物适用增值税低税率和简易办法征 收增值税政策的通知》（【财税 2009】9 号）规定，一般纳税人销售自产的用微 生物、微生物代谢产物、动物毒素、人或动物的血液或组织制成的生物制品，可 选择按照简易办法依照 3%征收率计算缴纳增值税。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-050 特此公告。 青岛蔚蓝生物股份有限公司董事会 2025 年 10 月 29 日 根据主管税务机关的通知和要求，公司部分产品由简易办法计算缴纳增值税 调整为一般计税办法计算缴纳增值税，增值税税率将由 3%调整至 13%。 二、对公司的影响 本次增值税税率调整不会影响公司 2024 年及以前年度业绩。预计自 2025 年起，公司部分产品适用税率将上调，对公司利润总额产生一定的间接影响。 为积极应对，公司已采取措施，包括优化产品定价与结构、强化税收管理与 成本控制、紧贴市 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-048 青岛蔚蓝生物股份有限公司 2025 年度第三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛蔚蓝生物股份有限公司（以下简称"公司"）根据上海证券交易所《上 市公司行业信息披露指引第十四号——食品制造》的要求，现将公司 2025 年第 三季度主要经营数据披露如下： | 地区 | | 2025 年第三季度 | | | | --- | --- | --- | --- | --- | | | 期初 | 增加 | 减少 | 期末 | | 东北 | 38 | 12 | 8 | 42 | | 华北 | 76 | 33 | 20 | 89 | | 华东 | 331 | 93 | 58 | 366 | | 华南 | 55 | 15 | 9 | 61 | | 华中 | 79 | 14 | 30 | 63 | | 西北 | 17 | 5 | 6 | 16 | | 西南 | 40 | 13 | 11 | 42 | | 总计 | 636 | 185 | 1 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-047 青岛蔚蓝生物股份有限公司 关于取消监事会、修订《公司章程》及修订、制定 公司部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛蔚蓝生物股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开 了第五届董事会第二十一次会议，审议通过了《关于取消监事会并修订<公司章 程>的议案》和《关于修订、制定公司部分治理制度的议案》，现将具体内容公告 如下： 一、取消监事会的情况 根据《中华人民共和国公司法》《关于新<公司法>配套制度规则实施相关过 渡期安排》以及证监会《上市公司章程指引（2025 年修订）》等相关规定，公司 将不再设置监事会，其职权由董事会审计委员会行使，并对《公司章程》部分条 款进行修订。 在公司股东会审议通过取消监事会事项前，公司监事会及监事仍将严格按照 法律法规及《公司章程》等规范性文件的要求继续履行职能，维护公司及全体股 东的合法利益。自公司股东会审议通过后，公司监事会将予以取消，现任各位监 事的职务自然免除 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-051 青岛蔚蓝生物股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2025 年 11 月 13 日 14 点 30 分 召开地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会 议室 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年11月13日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (一) 股东会类型和届次 2025年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 13 日 至2025 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-046 青岛蔚蓝生物股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于2025年10月28日在公司会议室以现场表决的方式召开，会议通知已于2025 年 10 月 23 日以邮件形式发出。本次会议应出席监事 3 人，实际出席 3 人。会议 由公司监事会主席原妤女士主持。会议召集召开程序及审议事项符合《中华人民 共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成的决 议合法有效。 二、监事会会议审议情况 根据《中华人民共和国公司法》《关于新<公司法>配套制度规则实施相关过 渡期安排》以及证监会《上市公司章程指引（2025 年修订）》等相关规定，公司 将不再设置监事会，其职权由董事会审计委员会行使，并对《公司章程》部分条 款进行修订。 在公司股东会审议通过取消监事会事项前，公司监事会及监事仍将严格按照 法律法规及《公司章程》等规范性文件的要求继续履 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-045 青岛蔚蓝生物股份有限公司 关于公司第五届董事会第二十一次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、审议并通过《关于公司<2025 年第三季度报告>的议案》 具体内容详见公司在上海证券交易所网站(www.sse.com.cn)披露的《青岛蔚 蓝生物股份有限公司 2025 年第三季度报告》。 本议案在提交董事会前已经公司第五届董事会审计委员会第十二次会议审 议通过。 表决票：5 票，赞成票：5 票，反对票：0 票，弃权票：0 票。 2、审议并通过《关于取消监事会并修订<公司章程>的议案》 根据《中华人民共和国公司法》《关于新<公司法>配套制度规则实施相关过 渡期安排》以及证监会《上市公司章程指引（2025 年修订）》等相关规定，公司 将不再设置监事会，其职权由董事会审计委员会行使，并对《公司章程》部分条 款进行修订。 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届董事会第二十一次 会议于 2025 年 10 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥363,599,708.49, an increase of 8.09% year-over-year[3] - Total profit for the period was ¥55,308,882.14, reflecting a significant increase of 103.70% compared to the same period last year[3] - Net profit attributable to shareholders was ¥35,062,856.99, marking a substantial growth of 205.02% year-over-year[3] - The basic earnings per share for the quarter was ¥0.14, up 180.00% from the previous year[3] - Total operating revenue for the first three quarters of 2025 reached RMB 1,015,793,037.32, an increase of 7.4% compared to RMB 945,618,593.20 in the same period of 2024[15] - The company reported a net profit margin of approximately 6.8% for the first three quarters of 2025, consistent with the previous year's performance[15] - The net profit for the first three quarters of 2025 reached CNY 82,929,836.08, an increase from CNY 61,067,866.90 in the same period of 2024, representing a growth of approximately 35.8%[16] - The company reported a total comprehensive income of CNY 82,710,492.97 for the first three quarters of 2025, up from CNY 61,009,443.78 in 2024, marking an increase of around 35.7%[17] - Basic and diluted earnings per share for the current period were CNY 0.24, compared to CNY 0.16 in the previous year, representing a growth of 50%[17] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,041,531,674.91, representing a 2.03% increase from the end of the previous year[4] - Total assets amounted to RMB 3,041,531,674.91 as of September 30, 2025, compared to RMB 2,981,000,556.19 at the end of 2024, showing an increase of 2.0%[13] - Total liabilities were RMB 1,140,329,570.96 as of September 30, 2025, compared to RMB 1,110,984,258.58 at the end of 2024, representing a rise of 2.6%[14] - The company's retained earnings increased to RMB 777,288,145.15 as of September 30, 2025, compared to RMB 740,811,881.65 at the end of 2024, reflecting a growth of 4.9%[14] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥33,756,771.81, down 46.59% due to increased raw material purchases[8] - The net cash flow from operating activities decreased to CNY 33,756,771.81 in 2025 from CNY 63,201,814.62 in 2024, reflecting a decline of approximately 46.6%[19] - The cash and cash equivalents at the end of the period were CNY 195,920,607.04, down from CNY 261,677,056.56 at the end of the same period last year, a decrease of approximately 25.1%[20] - The company incurred interest expenses of CNY 12,413,825.03, compared to CNY 16,374,941.90 in the previous year, showing a reduction of about 24.0%[16] - The total cash outflow from investing activities was CNY 721,034,075.45, an increase from CNY 684,590,067.62 in the previous year, indicating a rise of approximately 5.3%[20] - The net cash flow from financing activities turned negative at CNY -29,649,907.91, compared to a positive CNY 14,838,094.73 in the previous year, reflecting a significant change in financing strategy[20] Shareholder Information - The company has a total of 17,002 ordinary shareholders as of the reporting period[9] - The largest shareholder, Qingdao Kangdian Industrial Co., Ltd., holds 44.4% of the shares, totaling 112,407,400 shares[9] Operating Costs and Expenses - Total operating costs for the first three quarters of 2025 were RMB 946,888,887.21, up from RMB 881,905,556.31 in 2024, reflecting a year-on-year increase of 7.4%[15] - Research and development expenses increased to RMB 100,238,559.80 in the first three quarters of 2025, compared to RMB 81,303,889.41 in 2024, marking a growth of 23.3%[15] - Accounts receivable increased to RMB 408,070,064.31 as of September 30, 2025, compared to RMB 350,427,097.14 at the end of 2024, indicating a rise of 16.4%[12] - Inventory levels rose to RMB 216,743,499.06 as of September 30, 2025, compared to RMB 188,950,475.37 at the end of 2024, reflecting a growth of 14.7%[12] Non-Recurring Items - Non-recurring gains and losses for the period totaled ¥28,131,632.98, with government subsidies contributing significantly[6] - The company reported other income of CNY 20,752,969.81, an increase from CNY 17,042,774.30 in the previous year, representing a growth of approximately 21.0%[16] - The weighted average return on net assets increased to 2.01%, up 1.34 percentage points from the previous year[3]